Alyeska Investment Group
MLYS icon

Alyeska Investment Group’s Mineralys Therapeutics MLYS Stock Holding History

Alyeska Investment Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-37,500
Closed -$323K – 557
2023
Q4 		$323K Hold
37,500
– – ﹤0.01% 457
2023
Q3 		$357K Hold
37,500
– – ﹤0.01% 459
2023
Q2 		$639K Hold
37,500
– – ﹤0.01% 480
2023
Q1 		$587K Buy
+37,500
New +$631K 0.01% 409

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Alyeska Investment Group's MLYS Position: Q1 2024 in Review

Alyeska Investment Group sold out of Mineralys Therapeutics (MLYS) in Q1 2024, closing a stake of 37,500 shares — an estimated $323K sold.

Alyeska Investment Group first reported a position in MLYS in Q1 2023 and held it in 4 quarters. The position peaked at $639K in Q2 2023. 92 funds tracked by Wall St. Rank hold MLYS as of Q1 2024.

  • Alyeska Investment Group reported no remaining Mineralys Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 37,500 Mineralys Therapeutics shares in Q1 2024, an estimated $323K.
  • Alyeska Investment Group first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 4 quarters.
  • Alyeska Investment Group's Mineralys Therapeutics position peaked at $639K in Q2 2023.
  • 92 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2024.

Based on Alyeska Investment Group's 13F filing for Q1 2024, filed 15 May 2024.